Citi says Micron (IN) reported strong results but guided lower than the company's recently lowered estimates as the weakness in NAND inventory and a DRAM glut in the PC and handset end markets were worse than forecast. However, Citi…
The Oberoi Group recently introduced a new employment and skill development program called RISE (Refining and Investing in Skill Enhancement program). The initiative, launched on Friday, aims to provide education, training and certified hospitality careers to young people from diverse…
© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this website constitutes acceptance of us Terms of Use and Privacy Policy | CA Collection Notice and Privacy Notice | Do Not Sell/Share My Personal InformationFORTUNE is a trademark…
Open Editor's Digest for free Roula Khalaf, Editor of the FT, selects her favorite stories for this weekly newsletter. Elon Musk has entered the German election campaign in support of the far-right Alternative for Germany (AfD) party, marking the latest…
New York, New York–(Newsfile Corp. – December 20, 2024) – WHY: The Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of securities buyers of Sun Communities, Inc. (NYSE: NYSE:…
Todd Benzman of the Center for Immigration Studies discusses the cost of illegal immigration to the “bottom line” as the issue takes center stage in Congress' budget battle. Native American men in a decades-long trend that coincided with Increased immigrationAccording…
EMERGE appoints interim CFO Source link
Tesla Stock Slides. Why have shares fallen today? Source link
Aditya Birla Group Chairman Kumar Mangalam Birla said that when his grandfather Basant Kumar Birla passed away five years ago in 2019, he had only five pairs of kurta-dhoti and three suits. Birla said that his father, Aditya Vikram Birla,…
Lynparza (olaparib), a product of Fortune 500 pharmaceutical company Merck and Fortune 500 Europe AstraZeneca, showed significant improvements in overall survival in people with BRCA-mutated (gBRCAm), HER2-negative, high-risk early-stage cancers. of breast, clinical trial of 2024. data suggest. Jaime Grajales…
